In addition to the immunogenic transition of myeloid and lymphoid immune cells, rIL7 treatment promoted the formation of multicellular aggregates (clusters 14, 15, 21, and 22) that expressed multiple cell type lineage markers, including CT26 tumor markers (Rpl39l and Baiap2l1) and macrophage markers (H2-Aa and Cd68) (Supplementary Fig. 8c). The gene discussed is CD68; the disease is neoplasm.